An AHIP report found that the percentage of traditional Medicare beneficiaries who selected Medicare supplement plans increased to 41.4% in 2022, marking the fifth straight year of growth, and 57% of Medicare enrollees with no other coverage selected supplement policies in 2021. The majority of seniors with Medicare supplement plans were satisfied with their coverage, including 80% who said they were extremely or very satisfied, while 83% gave an excellent or good rating to their supplement coverage.

A report from the Robert Wood Johnson Foundation and the Urban Institute found that eight states exceeded their overall projected Medicaid disenrollment within the first eight months after restarting eligibility redeterminations, while 12 states surpassed overall projected disenrollment for children. The CMS previously estimated that 15 million Americans would lose Medicaid coverage once states resumed the redetermination process, but the latest KFF data showed that at least 21 million people were dropped from the program as of May 1.

Sen. Maggie Hassan, D-N.H., wrote in a letter to GSK CEO Emma Walmsley that the company is circumventing its promise to cap the price of its brand-name inhalers, as GSK has started offering a generic version of its Flovent inhaler through Prasco Laboratories. GSK "appears to be exploiting a licensing agreement with Prasco Laboratories in order to circumvent your public commitments and price-gouge families without access to affordable alternatives to Flovent," Hassan wrote.

Accord BioPharma and Intas Pharmaceuticals' Hercessi gained FDA approval as the latest interchangeable biosimilar for Herceptin, or trastuzumab. Hercessi was approved for the treatment of some patients with HER2-overexpressing breast cancer, metastatic breast cancer, and metastatic gastric or gastroesophageal junction adenocarcinoma.

Amolyt Pharma has received fast-track designation from the FDA for its parathyroid hormone receptor 1 agonist AZP-3601, or eneboparatide, to treat patients with hypoparathyroidism. The decision was based on data from a Phase 2 trial in which 93% of patients treated with eneboparatide were able to end standard treatment.